Pfizer reignites Prevenar war

Posted 20 January 2021 PM

There's no let-up in the legal battle over the blockbuster pneumococcal vaccine Prevenar 13, with Pfizer going back to court to appeal two aspects of a judgment it won significantly against rival MSD in October last year.

Although Pfizer successfully stopped MSD from supplying its 15-valent vaccine in Australia for the course of the patent, at the time, it said it would appeal aspects of the decision.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here